Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the progress and development of a hair loss treatment called GT20029. People are discussing updates on its status and speculating on how long it will take to become available.

The conversation discusses the lack of significant advancements in hair loss treatments since the introduction of finasteride 22 years ago, with many expressing frustration over the failure of new projects and skepticism about future developments. Some users mention hair transplants and other potential alternatives like Alfatradiol and Fluridil, but acknowledge finasteride's dominance in the market due to its effectiveness and affordability.

New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.

The conversation discusses new hair loss treatments, mentioning Breezula and a promising treatment called pyrilutamide.

The conversation discusses treatments to counteract skin wrinkles caused by Minoxidil use. Suggestions include Retinol-A and Zinc, but users seek specific products that have effectively halted wrinkling.

Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.

Discouragement regarding Pyrilutamide, a drug in development for hair loss, and the potential side effects of Finasteride. People discussed anecdotal experiences with Pyrilutamide as well as suggestions to wait out Phase 3 trials before making any conclusions.

Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.

Pyrilutamide, a potential hair loss treatment that is currently in development and may be available soon; an androgen receptor degrader which is also being developed as a potential treatment for hair loss; and the comparison between Pyrilutamide, finasteride, minoxidil, and RU58841.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

A user shared his experience of having two healthy children while continuously using finasteride (Fin) for hair loss, challenging fears about its potential impact on fetal development. The discussion that followed included various perspectives, with some users sharing similar experiences, others expressing concerns about potential risks, and some emphasizing the need for more substantial evidence before drawing conclusions.

The conversation discusses skepticism about the effectiveness of new hair loss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.

The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.

The conversation expresses frustration over the lack of progress in hair loss treatments, with specific mentions of Minoxidil, finasteride, and RU58841. Users discuss the slow development of new treatments and the potential of hair transplants.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.

The effects of Finasteride, a drug used to treat hair loss, prostate problems and other conditions. The post by iaskedadoctor describes the conversations they had with a Urologist about the effects of the drug on DHT levels throughout the body, how lower doses are beneficial in reducing side effects, how erectile dysfunction can be psychological as well as physiological, how morning erections are not necessarily important, and how persistent side effects appear to be rare. People also shared their experiences with taking Finasteride for hair loss, including potential side effects such as reduced ejaculate force and development of man boobs.

You cannot donate blood if you are taking finasteride or dutasteride due to potential risks to pregnant women. Finasteride has a shorter wait time to donate blood compared to dutasteride, and both oral and topical forms can disqualify you from donating.

The conversation is about acquiring GT20029 for hair loss treatment. The user is looking for information on how to obtain it.

User "Ant1pal" shares progress pictures of hair regrowth using Minoxidil, Estradiol valerate, and Spironolactone. Users discuss potential side effects and the possibility of localizing estrogen to hair follicles for better treatment.

The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It highlights an interview with Stemson Therapeutics CEO Geoff Hamilton about advancements in hair cloning technology.

A 17-year-old experiencing hair loss due to hard water was advised by a dermatologist to use a treatment containing Minoxidil and vitamins. A respondent confirmed the treatment's safety but warned that discontinuing Minoxidil could worsen hair loss.

The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.

The conversation is about hair loss treatments, including minoxidil, finasteride, dutasteride, tretinoin, stemoxydine, adenosine, castor oil, baicalin, and bimatoprost. The user shares their nightly and morning routines and discusses the role of DHT in hair loss.

The conversation is about updates on Scube3 related to hair loss. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

A 16-year-old experiencing hair loss seeks treatment advice. They decide to start with Serioxyl, Ketoconazole shampoo, and Eucapil, considering Minoxidil and Finasteride for later use.